Presentation is loading. Please wait.

Presentation is loading. Please wait.

Responsiveness and minimal important difference of the urticaria control test  Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,

Published byChristian Byron Wood Modified over 6 years ago

Similar presentations

Presentation on theme: "Responsiveness and minimal important difference of the urticaria control test  Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,"— Presentation transcript:

1 Responsiveness and minimal important difference of the urticaria control test 
Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz, MD, Tomasz Hawro, MD, Torsten Zuberbier, MD, Adriane Peveling-Oberhag, MD, Petra Staubach, MD, Marcus Maurer, MD, Karsten Weller, MD  Journal of Allergy and Clinical Immunology  Volume 140, Issue 6, Pages e11 (December 2017) DOI: /j.jaci Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig E1 UCT scores at baseline and 4 weeks after initiation of omalizumab treatment. Journal of Allergy and Clinical Immunology  , e11DOI: ( /j.jaci ) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig E2 Changes of the UCT score correlate with changes of the UAS7 score (A), the CU-Q2oL total score (B), and the DLQI score (C). Changes are measured from baseline to 4 weeks after the first omalizumab injection (300 mg). Journal of Allergy and Clinical Immunology  , e11DOI: ( /j.jaci ) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig E3 UCT scores improve with improved urticaria control (based on the PatGA-disease control on a 5-point Likert scale with the answer options “not at all,” “hardly,” “moderately,” “well,” “completely”). Journal of Allergy and Clinical Immunology  , e11DOI: ( /j.jaci ) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig E4 ROC curve. Area under the ROC curve for UCT score change from baseline to 4 weeks after initiation of omalizumab 300 mg treatment: 0.91 (95% CI, ). Journal of Allergy and Clinical Immunology  , e11DOI: ( /j.jaci ) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Responsiveness and minimal important difference of the urticaria control test  Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,"

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,
Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,

Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,
Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
Endoplasmic reticulum stress influences bronchial asthma pathogenesis by modulating nuclear factor κB activation So Ri Kim, MD, PhD, Dong Im Kim, MS, Mi.

Endoplasmic reticulum stress influences bronchial asthma pathogenesis by modulating nuclear factor κB activation So Ri Kim, MD, PhD, Dong Im Kim, MS, Mi.
D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Pharmacologic rationale for treating allergic and nonallergic rhinitis

Pharmacologic rationale for treating allergic and nonallergic rhinitis
Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials  Zuo-Tao Zhao, MD, PhD, Chun-Mei Ji, M Pharm,

Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials  Zuo-Tao Zhao, MD, PhD, Chun-Mei Ji, M Pharm,
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria  Ragip Ertas, MD, Kemal Ozyurt,

Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria  Ragip Ertas, MD, Kemal Ozyurt,
Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome  Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome  Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,
Shyam Joshi, MD, David A. Khan, MD 

Shyam Joshi, MD, David A. Khan, MD 
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Pavel Kolkhir, MD, Martin K

Pavel Kolkhir, MD, Martin K
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy  Allen Kaplan, MD, Dennis Ledford,

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy  Allen Kaplan, MD, Dennis Ledford,
Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial  Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial  Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

Similar presentations

Ads by Google